EMA Authorised: Minjuvi (tafasitamab) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

EMA authorised Minjuvi (tafasitamab) for diffuse large B-cell lymphoma with conditional approval and orphan designation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Minjuvi (tafasitamab)

Snippet

Status: Authorised. Therapeutic area: Lymphoma, Large B-Cell, Diffuse. MAH: Incyte Biosciences Distribution B.V.. Decision date: 15/12/2025. Conditional approval. Orphan medicine